Access cutting-edge mantle cell lymphoma treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Access mantle cell lymphoma specialists in Washington Dc at no cost
This study follows strict safety protocols and ethical guidelines
All study-related mantle cell lymphoma treatment provided free
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Sponsor: Hoffmann-La Roche
Check if you qualify for this mantle cell lymphoma clinical trial in Washington Dc, DC
If you're searching for mantle cell lymphoma treatment options in Washington Dc, DC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced mantle cell lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.